- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
- Interventions
- Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy
- Dietary Supplement · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,375
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
- Drug
- Lead sponsor
- Sequus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
- Conditions
- Breast Cancer
- Interventions
- pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3,294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2027
- U.S. locations
- 539
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
- Interventions
- Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 5,949 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 31
- States / cities
- San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
- Interventions
- MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Epcoritamab, Magnetic Resonance Imaging, Polatuzumab Vedotin, Positron Emission Tomography, Prednisone, Rituximab
- Procedure · Drug · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer, Thromboembolism
- Interventions
- docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2011
- U.S. locations
- 86
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Breast Cancer
- Interventions
- Cyclophosphamide, Docetaxel, Gemcitabine, Paclitaxel, Doxorubicin
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4,894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Stuart, Florida + 9 more
- Conditions
- Ganglioneuroblastoma, High Risk Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra), Paclitaxel (Taxol)
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 69
- States / cities
- Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 22 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more
- Conditions
- Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
- Interventions
- Adenosine stress test MRI
- Diagnostic Test
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Richmond, Virginia
- Conditions
- Sarcoma
- Interventions
- dactinomycin, busulfan, doxorubicin hydrochloride, etoposide, ifosfamide, melphalan, vincristine sulfate, autologous hematopoietic stem cell transplantation, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of Leicester
- Other
- Eligibility
- Up to 49 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
- Conditions
- Lymphoma
- Interventions
- rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hodgkin Disease
- Interventions
- Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Cincinnati, Ohio
- Conditions
- Adenocarcinoma
- Interventions
- Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin with a Taxane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 54
- States / cities
- Mobile, Alabama • Tucson, Arizona • Bakersfield, California + 49 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- Concord, California • Los Angeles, California • St. Helena, California + 14 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 58 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer
- Interventions
- Doxorubicin Hydrochloride, Cisplatin, Filgrastim, Pegfilgrastim, Paclitaxel
- Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 3,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Multiple Myeloma
- Interventions
- hLL1-DOX (the doxorubicin conjugate of milatuzumab)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Atlanta, Georgia • Hackensack, New Jersey + 2 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- doxorubicin hydrochloride, cyclophosphamide, filgrastim, paclitaxel albumin-stabilized nanoparticle formulation, trastuzumab, laboratory biomarker analysis, quality-of-life assessment
- Drug · Biological · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington